1187669-32-4

Basic information

• Product Name: 2-Bromo-1-(2-methoxypyridin-4-yl)ethanone
• Synonyms: 2-Bromo-1-(2-methoxypyridin-4-yl)ethanone
• CAS NO: 1187669-32-4
• Molecular Formula: C₈H₈BrNO₂
• Molecular Weight: 230.05862
• Mol File: 1187669-32-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Bromo-1-(2-methoxypyridin-4-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(2-methoxypyridin-4-yl)ethanone(1187669-32-4)
• EPA Substance Registry System: 2-Bromo-1-(2-methoxypyridin-4-yl)ethanone(1187669-32-4)

Safety Data

• Hazardous Substances Data: 1187669-32-4(Hazardous Substances Data)

Upstream product

• 105596-63-2 2-methoxy-isonicotinic acid 
• 764708-20-5 1-(2-methoxypyridin-4-yl)ethanone 
• 111887-72-0 1-(2-fluoropyridin-4-yl)ethan-1-one 
• 774238-83-4 2-fluoro-N-methyl-N-(methyloxy)-4-pyridinecarboxamide 
• 402-65-3 2-fluoropyridine-4-carboxylic acid 
• 193538-79-3 2-methoxypyridine-4-carbonyl chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 

Relevant articles and documents

4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS

4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders.

HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT

Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.